The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer

Sang Wun Kim, Jiheum Paek, Eun Ji Nam, Sung Hoon Kim, Jae Hoon Kim, Young Tae Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted carboplatin for cisplatin. The purpose of this study was to provide preliminary toxicity data of carboplatin-based IP chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. Study design: The toxicity data of 19 primary ovarian cancer patients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175 mg/m 2 on day 2, and IP paclitaxel 60 mg/m 2 on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period. Results: The toxicity data in a total of 118 cycles were analyzed. Grade 3 or 4 leukopenia, neutropenia, and pain were more common in the IP group than the IV group. There were seven catheter-related complications. Fourteen patients (73.7%) were able to complete six cycles or more of IP chemotherapy. Survival results in the IP group were compared with those from the IV group; a prolonged progression-free survival was observed (26.6 vs. 20.7 months; p = 0.038). Compared to the previous results with cisplatin-based IP chemotherapy, there was no significant difference in hematologic events. However, gastrointestinal, neurologic, and metabolic events in this study were definitely lower compared to those of cisplatin-based IP chemotherapy. Conclusions: Carboplatin-based IP and IV combination chemotherapy is feasible in patients with ovarian carcinoma after primary debulking surgery.

Original languageEnglish
Pages (from-to)195-199
Number of pages5
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume152
Issue number2
DOIs
Publication statusPublished - 2010 Oct

Fingerprint

Carboplatin
Ovarian Neoplasms
Drug Therapy
Cisplatin
Paclitaxel
Combination Drug Therapy
Leukopenia
Neutropenia
Platinum
Nervous System
Disease-Free Survival
Area Under Curve
Catheters
Carcinoma
Pain
Survival

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

@article{a2ebab06f35341dfaf002dcf86f4b00d,
title = "The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer",
abstract = "Objective: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted carboplatin for cisplatin. The purpose of this study was to provide preliminary toxicity data of carboplatin-based IP chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. Study design: The toxicity data of 19 primary ovarian cancer patients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175 mg/m 2 on day 2, and IP paclitaxel 60 mg/m 2 on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period. Results: The toxicity data in a total of 118 cycles were analyzed. Grade 3 or 4 leukopenia, neutropenia, and pain were more common in the IP group than the IV group. There were seven catheter-related complications. Fourteen patients (73.7{\%}) were able to complete six cycles or more of IP chemotherapy. Survival results in the IP group were compared with those from the IV group; a prolonged progression-free survival was observed (26.6 vs. 20.7 months; p = 0.038). Compared to the previous results with cisplatin-based IP chemotherapy, there was no significant difference in hematologic events. However, gastrointestinal, neurologic, and metabolic events in this study were definitely lower compared to those of cisplatin-based IP chemotherapy. Conclusions: Carboplatin-based IP and IV combination chemotherapy is feasible in patients with ovarian carcinoma after primary debulking surgery.",
author = "Kim, {Sang Wun} and Jiheum Paek and Nam, {Eun Ji} and Kim, {Sung Hoon} and Kim, {Jae Hoon} and Kim, {Young Tae}",
year = "2010",
month = "10",
doi = "10.1016/j.ejogrb.2010.05.033",
language = "English",
volume = "152",
pages = "195--199",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. / Kim, Sang Wun; Paek, Jiheum; Nam, Eun Ji; Kim, Sung Hoon; Kim, Jae Hoon; Kim, Young Tae.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 152, No. 2, 10.2010, p. 195-199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer

AU - Kim, Sang Wun

AU - Paek, Jiheum

AU - Nam, Eun Ji

AU - Kim, Sung Hoon

AU - Kim, Jae Hoon

AU - Kim, Young Tae

PY - 2010/10

Y1 - 2010/10

N2 - Objective: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted carboplatin for cisplatin. The purpose of this study was to provide preliminary toxicity data of carboplatin-based IP chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. Study design: The toxicity data of 19 primary ovarian cancer patients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175 mg/m 2 on day 2, and IP paclitaxel 60 mg/m 2 on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period. Results: The toxicity data in a total of 118 cycles were analyzed. Grade 3 or 4 leukopenia, neutropenia, and pain were more common in the IP group than the IV group. There were seven catheter-related complications. Fourteen patients (73.7%) were able to complete six cycles or more of IP chemotherapy. Survival results in the IP group were compared with those from the IV group; a prolonged progression-free survival was observed (26.6 vs. 20.7 months; p = 0.038). Compared to the previous results with cisplatin-based IP chemotherapy, there was no significant difference in hematologic events. However, gastrointestinal, neurologic, and metabolic events in this study were definitely lower compared to those of cisplatin-based IP chemotherapy. Conclusions: Carboplatin-based IP and IV combination chemotherapy is feasible in patients with ovarian carcinoma after primary debulking surgery.

AB - Objective: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted carboplatin for cisplatin. The purpose of this study was to provide preliminary toxicity data of carboplatin-based IP chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. Study design: The toxicity data of 19 primary ovarian cancer patients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175 mg/m 2 on day 2, and IP paclitaxel 60 mg/m 2 on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period. Results: The toxicity data in a total of 118 cycles were analyzed. Grade 3 or 4 leukopenia, neutropenia, and pain were more common in the IP group than the IV group. There were seven catheter-related complications. Fourteen patients (73.7%) were able to complete six cycles or more of IP chemotherapy. Survival results in the IP group were compared with those from the IV group; a prolonged progression-free survival was observed (26.6 vs. 20.7 months; p = 0.038). Compared to the previous results with cisplatin-based IP chemotherapy, there was no significant difference in hematologic events. However, gastrointestinal, neurologic, and metabolic events in this study were definitely lower compared to those of cisplatin-based IP chemotherapy. Conclusions: Carboplatin-based IP and IV combination chemotherapy is feasible in patients with ovarian carcinoma after primary debulking surgery.

UR - http://www.scopus.com/inward/record.url?scp=77957752309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957752309&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2010.05.033

DO - 10.1016/j.ejogrb.2010.05.033

M3 - Article

C2 - 20576343

AN - SCOPUS:77957752309

VL - 152

SP - 195

EP - 199

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 2

ER -